Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8] Market Opportunities - The AI ecosystem is expected to reshape business, government, and consumer operations globally, indicating vast investment opportunities [2] - The narrative suggests that investors may soon regret not owning shares in a specific AI company that is positioned to capitalize on this technological wave [9]

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +24.11%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.38 per share when it actually produced a loss of $0.36, delivering a surprise of +5.26%.Over the last four quarter ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone payment from partner Roche (RHHBY). For Q4, the Salt Lake City, Utah-based biotech reported $35.5M in ...

Key Takeaways RXRX reported a Q4 loss of 21 cents per share, beating estimates and narrowing from last year.Recursion revenues rose to $35.5M on a $30M Roche milestone payment and contributions from Sanofi.Recursion Pharmaceuticals ended 2025 with $753.9M in cash, funding operations into early 2028.Recursion Pharmaceuticals (RXRX) reported a loss of 21 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 28 cents. The company had incurred a loss of 53 cents ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker2Good morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of large-scale biological data generation, machine learning, and compute to better understand the complexity of biology. We have also deliber ...

Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Exhibit 99.1 Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SALT LAKE CITY, February 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq : RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025. Recursion will host an earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion's X ...